Kyntra Bio stock (US3156631046): Q1 2026 revenue rises to $3.7M amid pipeline advances

Kyntra Bio, formerly FibroGen, posted Q1 2026 revenue of $3.7 million, up from $2.7 million year-over-year, with net loss at $15.1 million. Pipeline updates include Phase 2 progress for FG-3246 in prostate cancer and Phase 3 plans for roxadustat in MDS.

Kyntra Bio reported first quarter 2026 financial results, showing revenue from continuing operations of $3.7 million, an increase from $2.7 million in the prior-year period, primarily driven by higher drug product revenue, according to StockTitan as of May 2026. The company, which rebranded from FibroGen earlier this year, also narrowed its net loss from continuing operations to $15.1 million. Cash reserves are projected to fund operations into 2028. These results are relevant for US investors tracking biotech firms with exposure to oncology and hematology markets.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: FibroGen, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Oncology, anemia treatments
• Key revenue drivers: Drug product sales, pipeline royalties
• Home exchange/listing venue: Nasdaq (KYNB)
• Trading currency: USD

Kyntra Bio: core business model

Kyntra Bio focuses on developing novel therapeutics in oncology and anemia-associated diseases. Its lead candidates include FG-3246, an antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer (mCRPC), currently in a Phase 2 monotherapy trial, per the Q1 2026 update from MarketScreener as of May 2026. The company also advances roxadustat, an oral therapy for anemia in lower-risk myelodysplastic syndromes (MDS). Previously known as FibroGen, it rebranded to Kyntra Bio in January 2026 and changed its ticker to KYNB.

The business model relies on collaborations for commercialization, with revenue from drug supply and potential milestones. This structure provides US investors exposure to late-stage biotech assets amid growing demand for targeted cancer therapies.

Main revenue and product drivers for Kyntra Bio

Q1 2026 revenue reached $3.7 million from continuing operations, up 37% year-over-year, fueled by drug product sales, as detailed in the company's 8-K filing reported by StockTitan as of May 2026. Net loss stood at $15.1 million, reflecting R&D investments. Cash and equivalents are sufficient into 2028, supporting pipeline execution without near-term dilution risks.

Key drivers include FG-3246 progress and roxadustat development. Positive data from prior combinations with enzalutamide bolster the ongoing Phase 2 trial in mCRPC, with interim readout expected in Q4 2026. For roxadustat, FDA feedback has shaped a pivotal Phase 3 protocol for lower-risk MDS anemia, targeting start in H2 2026.

Industry trends and competitive position

The antibody-drug conjugate (ADC) space is expanding rapidly, with CD46-targeted therapies addressing unmet needs in prostate cancer. Kyntra Bio's FG-3246 differentiates via its first-in-class profile, enrolling in Phase 2 amid competition from established players like AstraZeneca and Merck. US market growth in mCRPC treatments supports long-term potential.

In MDS anemia, roxadustat's oral HIF-PH inhibitor mechanism offers convenience over injectables. Finalizing Phase 3 post-FDA input positions it competitively, with partnerships eyed for execution. These trends align with US biotech sector emphasis on precision oncology.

Why Kyntra Bio matters for US investors

Listed on Nasdaq as KYNB, Kyntra Bio provides US investors direct access to innovative oncology pipeline with catalysts in 2026. Its cash runway into 2028 reduces funding risks, while focus on high-prevalence diseases like prostate cancer taps into a $10B+ US market. Rebranding signals strategic pivot post-FibroGen challenges.

Conclusion

Kyntra Bio's Q1 2026 results highlight revenue growth and pipeline momentum, with FG-3246 Phase 2 interim data and roxadustat Phase 3 initiation as key 2026 milestones. Cash position supports advancement without immediate financing needs. Investors monitoring biotech will note these developments in oncology and hematology.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.